PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION
Abstract
Objective: to conduct a pharmacoeconomic analysis of lenvatinib (Lenvima) in advanced progressive radio iodine refractory differentiated thyroid cancer in the Russian Federation.
Methods. Cost-effectiveness ratio (CER) and budget impact analysis (BIA) were performed. All calculations were made in the MS Excel model. CER compared lenvatinib 24 mg/daily, sorafenib 800 mg/daily and Other chemotherapies mix. BIA compared two scenarios: 1) common practice consisting of sorafenib and Other chemotherapies mix; 2) new practice where lenvatinib is used in 6.25% patients. Costs of drugs, visits to oncologist and hospitalization were calculated both in CER and BIA. Time horizon was 2 years for CER and 5 years for BIA.
Results. Lenvatinib is a new highly effective target drug for the monotherapy of the radioiodine refractory differentiated thyroid cancer. Lenvatinib significantly increases progression free survival, thus providing in the proposed model, 1628 additional years of life for patients per 5 years. Additional costs at the same time constitute 5 213 900 000 rub. (670.5 to 1184.3 million rubles per year). Calculated unit lenvatinib efficiency stands at 64.95% less than that of the comparisons targeted drug (sorafenib).
About the Authors
M. Yu. Frolov
Volgograd State Medical University of the Ministry of Health Russian Federation
Russian Federation
Russian Federation
PhD (candidate of medical sciences), assistant professor (FUV module) of Clinical pharmacology and intensive therapy department,
pl. Pavshikh Bortsov, 1, g. Volgograd, 400131
V. A. Rogov
Volgograd State Medical University of the Ministry of Health Russian Federation
Russian Federation
Russian Federation
candidate of pharmaceutical sciences of management and economics of pharmacy, medical and pharmaceutical merchandising department,
pl. Pavshikh Bortsov, 1, g. Volgograd, 400131
References
1. Alieva S.B., Alymov Yu.V., Mudunov A.M. linical guidelines for the diagnosis and treatment of thyroid cancer [Klinicheskie rekomendatsii po diagnostike i lecheniyu raka shchitovidnoi zhelezy (In Russian)]. Moscow. 2014; 27s.
2. Balykina Yu.E., Kolbin A.S. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / Pharmacoeconomics. Modern pharmacoeconomics and pharmacoepidemiology. 2013; 6 (4): 3-6.
3. Goryainov S.V., Rebrova O.Yu. Pediatricheskaya farmakologiya. 2012; 9 (2): 6-9.
4. Kaprina A.D., Starinskii V.V., Petrovskaya G.V. Malignancies in Russia in 2014 (morbidity and mortality) [Zlokachestvennye novoobrazovaniya v Rossii v 2014 g. (zabolevaemost' i smertnost') (In Russian)]. Moscow. 2016; 250 s.
5. Kaprina A.D., Starinskii V.V., Petrovskaya G.V. Status of cancer care the population of Russia in 2014 [Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2014 godu (In Russian)]. Moscow. 2015; 236 s.
6. Lapach S.N., Chubenko A.V., Babich P.N. Statistics in science and business. A Practical Guide [Statistika v nauke i biznese. Prakticheskoe rukovodstvo (In Russian)]. Moscow. 2002; 640 s.
7. Mudunov A.M., Rumyantsev P.O., Podvyaznikov S.O. Opukholi golovy i shei. 2015; 5 (3): 59-63.
8. Rumyantsev P.O. Klinicheskaya i eksperimental'naya tireoidologiya. 2015; 11 (2): 25-32.
9. Yagudina R.I. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / Pharmacoeconomics. Modern pharmacoeconomics and pharmacoepidemiology. 2011; 4 (2): 9-12.
10. Brose M.S., Nutting C.M., Jarzab B. et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014; 384 (9940): 319-328.
11. Brown R.L., de Souza J.A., Cohen E.E.W. Thyroid Cancer. Burden of Illness and Management of Disease. Journal of Cancer. 2011; 2: 193-199.
12. Bucher H.C., Gordon H.G., Lauren E.G. et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Clinical Epidemiology. 1997; 50 (6): 683-691.
13. Cabanillas M.E., Habra M.A. Lenvatinib: Role in thyroid cancer and other solid tumors. Cancer Treat Rev. 2016 Jan; 42: 47-55. DOI: 10.1016 - j.ctrv.2015.11.003. Epub 2015 Dec 2.
14. Carr B.I., Carroll S., Muszbek N. et al. Economic evaluation of sorafenib in unresectable hepatocellular carcinoma. Journal of gastroenterology and hepatology. 2010; 25 (11): 1739-1746.
15. Elliot M., Larson B., Kazi D. S. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015; 93: 118-124.
16. Fordham B.A., Kerr C.L., de Freitas H.M. et al. Health state utility valuation in radioactive iodine-refractory differentiated thyroid cancer. Patient Prefer Adherence. 2015 Nov 3; 9: 1561-1572. DOI: 10.2147/PPA.S90425.
17. Frampton J.E. Lenvatinib: A Review in Refractory Thyroid Cancer. Target Oncol. 2016 Feb; 11 (1): 115-22. DOI: 10.1007/s11523-015-0416-3.
18. Kerr C., Fordham B., de Freitas H.M. et al. Health state utility valuation in radio-iodine refractory differentiated thyroid cancer (RRDTC). ISPOR 17th Annual European Congress. Amsterdam. 12 November 2014.
19. Matsui J., Minoshima Y., Tsuruoka A. et al. A:3614 Multi-targeted kinase inhibitor E7080 showed anti-tumor activity against medullary thyroid carcinoma and squamous thyroid carcinoma cell line based on RET and VEGFR2 tyrosine kinase inhibition. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research. Washington, DC: American Association for Cancer Research. 2010.
20. Nersesyan K., Robinson D., Wolfe G. et al. Epidemiology and treatment of radioactive iodine-refractory differentiated thyroid cancer in the eu5. URL: http://www.kantarhealth.com/docs/publications-citations/nersesyan---epi-and-tx-of-rr-dtc-in-eu5---eisai--ispor.pdf?sfvrsn=0. Accessed: 12.01.16.
21. Schlumberger M., Tahara M., Wirth L. et al. Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer. The New England Journal of Medicine. 2015; 621-630.
22. Sullivan S.D., Mauskopf J.A., Augustovski F. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014; 17 (1): 5-14.
23. World Health Organization. Who choice Unit Costs Database. http://www.who.int/choice/costs/en/. Accessed: 12.01.16.
24. Yeung K.T., Cohen E.E. Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma. Clin Cancer Res. 2015 Dec 15; 21 (24): 5420-5426. DOI: 10.1158/1078-0432.CCR-15-0923.
For citation:
Frolov M.Y., Rogov V.A. PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2016;9(1):24-32. (In Russ.) https://doi.org/10.17749/2070-4909.2016.9.1.024-032
Views: 633
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 